To analyze the clinical effect of Shenqi Fuzheng Kang’ai Decoction（参芪扶正抗癌汤）combined with bevacizumab in the treatment of advanced colorectal cancer with Qiand blood deficiency syndrome.

The clinical data of 98 patients with advanced colorectal cancer who were admitted to the Affiliated Hospital of Nantong University from January 2022 to January 2024 was retrospectively analyzed.According to the treatment methods，they were divided into the conventional group（48 cases）and the combined group（50 cases）.Both groups were treated with XELOX chemotherapy.The conventional group was treated with bevacizumab，and the combined group was treated with Shenqi Fuzheng Kang’ai Decoction on this basis.The TCM syndrome score，tumor markers，T lymphocyte subsets，chemotherapy tolerance and quality of life score，clinical efficacy，adverse reactions and survival analysis of the two groups were observed.

After treatment，the TCM syndrome score and the levels of carcinoembryonic antigen（CEA），carbohydrate antigen 125（CA125），alpha-fetoprotein（AFP）and cytokeratin 19 fragment antigen 21-1（CYFRA21-1）in the combined group were lower than those in the conventional group（P<0.05）.The levels of CD3⁺and CD4⁺，the ratio of CD4⁺/CD8⁺，the scores of Karnofsky performance scale（KPS）and World Health Organization Quality of Life-BREF（WHOQOL-BREF）and the total effective rate in the combined group were higher than those in the conventional group（P<0.05）.There was no significant difference in the total incidence of adverse reactions between the two groups（P>0.05）.The progression-free survival（PFS）of the combined group was longer than that of the conventional group（P<0.05）.

Shenqi Fuzheng Kang’ai Decoction combined with bevacizumab in the treatment of advanced colorectal cancer with Qi and blood deficiency syndrome can effectively relieve the clinical symptoms of patients，improve the immunity，reduce the levels of tumormarkers，improve the clinical efficacy and quality of life，prolong the survival of patients，and has high safety.

To establish the infrared fingerprint spectra of standard decoctions of Xiangfu（Cyperi Rhizoma）and its processed products，and quickly identify the standard decoctions of Xiangfu（Cyperi Rhizoma）and its processed products.

Infrared fingerprint spectra were established for the decoctions of Xiangfu（Cyperi Rhizoma），wine-processed Xiangfu（Cyperi Rhizoma），vinegar-processed Xiangfu（Cyperi Rhizoma）and four-processed Xiangfu（Cyperi Rhizoma）.The differences among the average infrared spectra of the decoctions of Xiangfu（Cyperi Rhizoma），wine-processed Xiangfu（Cyperi Rhizoma），vinegar-processed Xiangfu（Cyperi Rhizoma）and four-processed Xiangfu（Cyperi Rhizoma）were analyzed using OMNIC 9.2 software.The common peaks of Xiangfu（Cyperi Rhizoma）and its processed product decoctions were identified using Spectrum forWindow 3.02 software and the relative peak heights were calculated.The differences among the processed Xiangfu（Cyperi Rhizoma）decoctions were compared using principal component analysis，orthogonal partial least squares-discriminant analysis and clustering analysis.

A total of 12 common peaks were identified and standardized for the decoctions of Xiangfu（Cyperi Rhizoma），vinegar-processed Xiangfu（Cyperi Rhizoma），wine-processed Xiangfu（Cyperi Rhizoma）and four-processed Xiangfu（Cyperi Rhizoma）using baseline correction and normalization.The differences were obvious in the 1700-1000 cm^-1 waveband，and fourmain contribution wavebands were selected，including2929 cm^-1，1053 cm^-1，997 cm^-1 and 1639 cm^-1.The processed Xiangfu（Cyperi Rhizoma）decoctionswere all clustered into four categories through analysis.

There are obvious differences among the decoctions of Xiangfu（Cyperi Rhizoma），vinegar-processed Xiangfu（Cyperi Rhizoma），wine-processed Xiangfu（Cyperi Rhizoma）and four-processed Xiangfu（Cyperi Rhizoma），and they can be quickly identified using infrared spectroscopy.The method is fast，effective and accurate.

To investigate the correlation between different types of refractory peptic ulcer（RPU）and clinical manifestations，and to provide clinical basis for the prevention and treatment of this disease in modern medicine.

A crosssectional study was conducted to retrospectively collect the general data，clinical medical records，tongue and pulse conditions，TCM syndromes and other related factors of130 patients with RPU who were hospitalized in the Department of Gastroenterology of Zhengzhou People's Hospital from January 1，2020 to September30，2023.The collected data was statistically analyzed to explore the relationship between different types of RPU and clinical manifestations.

（1）There was no significant difference between the types of RPU and the distribution of tongue and pulse.（2）In terms of disease location syndrome elements，the mostusual disease location syndrome elements of RPU were heart and stomach（100.00%），the others were spleen（43.08%）and liver（30.00%）；in terms of disease nature syndrome elements，the most usual disease nature syndrome elements were spleen and stomach weakness（cold）syndrome（28.46%），followed by liver-stomach disharmony syndrome（21.54%），blood stasis in stomach collateral syndrome（16.15%），damp-heat in spleen and stomach syndrome（14.62%），stomach Yin deficiency syndrome（10.77%），liver-stomach heat stagnation syndrome（8.46%）.（3）There was no significant difference in hypertension，coronary heart disease and weight among the three groups（P>0.05）.There were significant differences in gender，Helicobacter pylori（Hp）infection，smoking history，diabetes，age，height and oral non-steroidal anti-inflammatory drugs（NSAIDs）（P<0.05）.Oralad ministration of NSAIDs is a risk factor for refractory compound ulcer and refractory duodenalulcer.Coronary heart disease，height and Hp infection are risk factors for refractory gastric ulcer.

The patients with Hp infection have a higher probability of refractory gastric ulcer.The patients with smoking history，diabetes and NSAIDs are more likely to develop refractory duodenal ulcer.Patients with different ages and heights are prone to RPU types.Oral administration of NSAIDs is a risk factor for refractory compound ulcer and refractory duodenal ulcer.Coronary heart disease，height and Hp infection are risk factors for RPU.

This study aims to explore the potential categories of five pattern personalities and analyze the differences of each category on the Big Five Personality.

A total of 963 volunteers were recruited to participate in the study.The survey was conducted using the Five Pattern Personalities Inventory and Big Five Personality Inventory.The latent categories of five pattern personalities were analyzed using latent profile analysis.

1）It was found that there were five latent categories of five pattern personalities：“low Yang-low Shaoyin-high Taiyin group”（12.56%），“low Yang-high Yin group”（27.73%），“high Yang-high Shaoyin low Taiyin group”（37.49%），“high Yang-high Yin group”（5.93%），“high Yanglow Yin group”（16.34%）.2）The five latent categories of five pattern personality exhibited significant differences in each dimension of the Big Five Personality（P<0.001）.The“low Yang group”（categories 1 and 2）demonstrated significantly lower levels of openness，extroversion and agreeableness compared to the“high Yang group”（categories 3 and 5）（P<0.001），while scoring higher on neuroticism than the“high Yang group”.Additionally，the rigor score for the“high Yang-high Shaoyin low Taiyin group”was significantly higher than other groups，whereas it was lower for the“low Yang-low Shaoyin high Taiyin group”.Furthermore，extraversion and agreeableness scores were lower for“high Yang-high Yin group”compared to“high Yang group”but higher than those for“low Yang group”；neuroticism scores were lower than those for“low Yang group”but higher than those for“high Yang group”as well.

There are five potentially categories of five pattern personalities.These different latent categories were significantly different on the Big Five Personality.

To investigate the effect of Zijinlong Tablets（紫金龙片）combined with intravenous immunoglobulin in the treatment of lower respiratory tract infection in the elderly.

Totally 302 elderly patients with lower respiratory tract infections admitted to the hospital from March 2021 to March 2023 were selected and randomly grouped，each with 151 cases.Based on conventional treatment，the control group was given intravenous immunoglobulin，and the study group received Zijinlong Tablets combined with intravenous immunoglobulin.Then the clinicalefficacy，ratio of forced expiratory volume in the firstsecond to forced vital capacity（FEV₁/FVC），peak expiratory flow（PEF），maximum voluntary ventilation（MVV），arterial partial pressure of oxygen（PaO₂），arterial partial pressure of carbon dioxide（PaCO₂），interleukin-6（IL-6），C-reactive protein（CRP），interleukin-1（IL-1），procalcitonin（PCT），immunoglobulin-（Ig）A，IgG，IgM and T-lymphocyte subsets（CD3⁺，CD4⁺，CD8⁺）were compared.

The study group reported a higher overall efficacy rate than the control group（93.38% vs85.43%，P<0.05）.An increase in PEF，MVV and FEV₁/FVC were observed in all patients after treatment，and the increase was more notable in the study group than those in the controlgroup（P<0.05）.An elevation in PaO₂ and a decrease PaCO₂ were detected in all patients，and both improvements were more remarkable in the study group than those in the control group（P<0.05）.After treatment，the levels of IL-6，CRP，IL-1 and PCT showed a decrease in all patients，and the three parameters were all lower in the study group than those in the control group（P<0.05）.The levels of IgA，IgG and IgM demonstrated an increase in all patients，and were all larger in the study group than those in the control group（P<0.05）.An elevation in CD3⁺and CD4⁺and a decrease CD8⁺were found in all patients，and both improvements were more obvious in the study group than those in the control group（P<0.05）.

The application of Zijinlong Tablets combined with intravenous immunoglobulin in the treatment of lower respiratory tract infection in the elderly can effectively improve the pulmonary function and arterial blood gas indexes，attenuate the cellular inflammatory response，ameliorate the body immune function and promote the recovery of the patients.

To explore the clinical efficacy of Jianpi Lishi Jiedu Decoction（健脾利湿解毒汤）combined with pidotimod in the treatment of low-grade squamous intraepithelial lesions（LSIL）of the cervix combined with high-risk human papillomavirus（HPV）infection.

A totalof130 cases of LSIL complicated with high-risk HPV infection admitted to the hospital from January 2022 to September 2023 were included and divided into two groups using the computer random number table method，with 65 cases in each group.The control group was treated with pidotimod，while the observation group was treated with Jianpi Lishi Jiedu Decoction on the basis of the control group.The treatment lasted for 3 months.The clinical efficacy of two groups，the traditional Chinese medicine syndrome score and serum inflammatory factor levels［high-sensitivity C-reactive protein（hs-CRP），interleukin-12（IL-12）and tumor necrosis factorα（TNF）-α）］and changes in viral load were compared.

①The total effective rate of the observation group was 93.85%，which was higher than that（81.54%）of the control group（χ²＝4.561，P＝0.033）.②The difference in traditional Chinese medicine syndrome scores for vaginal discharge，itching，fatigue，edema and loose stools in the observation group was lower than that in the control group［（1.13±0.13）points vs.（2.05±0.16）points，（1.09±0.11）points vs.（1.65±0.15）points，（1.01±0.19）points vs.（1.66±0.22）points，（0.68±0.17）points vs.（1.13±0.19）points，（0.89±0.18）points vs.（1.38±0.14）points］（t＝35.979～17.324，all P<0.01）.③The serum levels of TNF-α and hs-CRP of the observation group were all lower than those of the control group［（1.13±0.36）pg/mL vs.（1.72±0.41）pg/mL，（2.19±0.45）mg/L vs.（4.24±0.87）mg/L］（t＝8.718-16.874，all P<0.01），and the serum IL-12 levels were higher than the control group［（16.52±5.03）pg/mL vs.（14.25±5.16）pg/mL］（t＝-2.540，P＝0.006）.④The recurrence rate［4.61%（3/65）］in the observation group was significantly lower than that［16.92%（11/65）］in the control group（χ²＝5.123，P＝0.024）.The HPV viral load in the observation group was lower than that in the control group［（1.85±0.59）Igcopies/mL vs.（2.73±0.65）Igcopies/mL］（t＝-8.082，P<0.01），and the seroconversion rate was higher than that in the control group（69.23% vs.43.08%）（χ² ＝9.029，P＝0.003）.

The combination of Jianpi Lishi Jiedu Decoction and pidotimod in the treatment of LSIL complicated with high-risk HPV infection has a definite therapeutic effect.It can restore the patient's immune inflammatory balance and reduce the HPV viral load.

To observe the clinical effect and safety of Chaipo Decoction（柴朴汤）combined with Sulidi in the treatment of bronchial asthma.

A total of 92 patients with bronchial asthma admitted from March 2022 to March 2024 were included in this study.The patients were divided into two groups by random number table method，namely，the Sulidiere group receiving Sulidiere treatment and the Chaipo Decoction group receiving Sulidiere treatment combined with Chaipo Decoction，with 46 cases in each group.The patient data of each group was observed，including the clinical efficacy，adverse reactions and TCM symptom score before and after treatment（sleeping at night and waking up in the morning with severe cough，dry cough with little or no phlegm，rib distension，restlessness and chest tightness，and discomfort in the throat，etc.）and sputum inflammatory factor index changes，pulmonary function index and index of immune function changes，asthma control test（ACT）and Mini Asthma Quality of Life Questionnaire（Mini AQLQ）.

The total effective rate of the Chaipo Decoction group was higher than that of the Sulidiere group（P<0.05）.The adverse reaction rate of patients in Chaipo Decoction group was similar to that in Sulidiere group（P>0.05）.Before treatment，the patients in both groups received traditional Chinese medicine syndrome scores（sleeping at night and waking up in themorning with severe cough，dry cough with little or no phlegm，rib distension，restlessness and chest tightness，and discomfort in the throat，etc.），interleuin 6（IL-6），interleuin 17（IL-17），tumour necrosis factor-α（TNF-α）and other indicators of sputum factors，forced vital capacity（FVC）and forced expiratory volume in one second（FEV1），percentage of forced expiratory volume at the first second to forced vital capacity（FEV1%）and other pulmonary function indicators，CD3⁺，CD4⁺，CD8⁺，CD4⁺/CD8⁺and other immune function indicators，ACT and Mini AQLQ scores were not significant（P>0.05）.After treatment，TCM syndrome scores（coughing up atnight and in the morning，dry cough with little or no sputum，hypochthmic fullness，upset chest tightness，pharyngeal distress，etc.），sputum inflammatory factor indexes（IL-6，IL-17，TNF-α），lung function indexes（FVC，FEV1，FEV1%），and immune function indexes（CD3⁺，CD4⁺，CD8⁺，CD4⁺/CD8⁺）of all patients in each group，ACT and Mini AQLQ scores were improved.After treatment，patients in the Chaipo Decoction group had TCM syndrome scores（sleeping at night and waking up in the morning with severe cough，dry cough with little or no phlegm，rib distension，restlessness and chest tightness，and discomfort in the throat，etc.），sputum inflammatory factor indexes（IL-6，IL-17，TNF-α），lung function indexes（FVC，FEV1，FEV1%）and immune function indexes（CD3⁺，CD4⁺，CD8⁺，CD4⁺/CD8⁺），ACT and Mini AQLQ scores were better than those in the Seridial group（P<0.05）.

The clinical effect of Chaipo Decoction combined with Sulidi in the treatment of bronchial asthma is good.The inflammation of the patients is significantly improved.The symptoms and lung function are improved.The disease is controlled.The quality of life is improved.The adverse reactions are less.The treatment is relatively safe and reliable.

To investigate the efficacy and safety of Sanhuangtangshenkang（三黄糖肾康）combined with Dapagliflozin in the treatment of Qi deficiency and blood stasis type of early diabetic nephropathy（DN）.

A randomized，double-blind and placebo-controlled clinical trial was conducted involving 120 patients from the Endocrinology and Nephrology Departments at Taizhou Hospital of Traditional Chinese Medicine from June 2021 to June 2023.The participants were allocated into two groups.The experimental group（60 patients）received standard care augmented with Sanhuangtangshenkang and Dapagliflozin，while the control group（60 patients）was treated with standard care plus placebo granules and Dapagliflozin.The duration of treatmentwas 12 weeks.The primary endpoints included the efficacy of treatment，the renal function，the inflammatory markers，the enhancement of traditional Chinese medicine（TCM）syndromes，and the frequency of adverse events.

A total of 117 patients were successfully enrolled，59 in the experimental group and 58 in the control group.The experimental group showed a significantly higher overall effective rate compared to the control group（98.30% versus70.68%，P<0.05）.Biochemical indicators such as the urine albumin-to-creatinine ratio（UACR），24-hour urinary microalbumin（UMA）and 24-hour urinary protein were significantly improved in the experimental group compared to those in the control group after 12 weeks of treatment（P<0.05）.Inflammatory markers including serum amyloid A（SAA），interleukin-6（IL-6），C-reactive protein（CRP）and homocysteine（Hcy）also showed more significant reductions in the experimental group，especially after 12 weeks of treatment（P<0.05）.The improvements in renal function and other biochemical indicators，such as glycated hemoglobin（HbA1c），estimated glomerular filtration rate（eGFR）and total cholesterol（TC），were also notably better in the experimental group（P<0.05）.TCM symptom scores further confirmed the improvement in various indicators in the experimental group after treatment（P<0.05）.Although there was no statistically significant difference in the incidence of adverse reactions between the two groups（P>0.05）.The experimental group exhibited a lower rate of adverse reactions（3.38%）compared to the control group（8.62%）.

The combination of Sanhuangtangshenkang with Dapagliflozin is highly effective and safe for improving renal function，glycemic control and TCM syndromes in patients with early-stage DN characterized by Qi deficiency and blood stasis，demonstrating both enhanced safety and superior efficacy.

To explore the intervention and mechanism of YiqiBushen Tongluo Decoction（益气补肾通络方）in the treatment of varicocele infertility inmice.

A total of60 Sprague Dawley（SD）rats were selected and divided into sham operation group，model group，Yiqi Bushen Tongluo Decoction low dose group，medium dose group and high dose group according to random number table method，with 12 cases in each group.The drug was given by intragastric administration 48 h after the modeling was completed and continuously used for60 d.The testis and epididymis quality，sperm quality，spermatogenic cell apoptosis index and the levels of malondialdehyde（MDA），superoxide dismutase（SOD）and nitric oxide（NO）in testicular tissue were compared among all groups.

The testis quality，epididymal quality，sperm concentration and sperm motility in the model group were lower than those in the sham operation group，and the spermatogenic apoptosis index was higher than those in the sham operation group，with statistical significance（P<0.05）.Compared with those in the model group，the testis quality，epididymal quality，sperm concentration and sperm motility were significantly increased in the Yiqi Bushen Tongluo Decoction low dose，medium dose and high dose groups，and the spermatogenic apoptosis indexwas significantly decreased，with statistical significance（P<0.05）.The levels of MDA and NO in the model group were higher than those in the sham operation group，and the SOD level was lower than that in the sham operation group，with statistical significance（P<0.05）.Compared with those in the model group，the levels of MDA and NO were significantly decreased in the Yiqi Bushen Tongluo Decoction low dose，medium dose and high dose groups，and the SOD level was significantly increased，with statistical significance（P<0.05）.

Yiqi Bushen Tongluo Decoction can improve the sperm quality of mice with varicocele infertility.Itsmechanism of action is mainly related to inhibiting spermatogenic cell apoptosis，anti-oxidative stress and reducing NO level.